Drug Profile

Atezolizumab/Tiragolumab - Roche

Alternative Names: Atezolizumab/Tiragolumab; MPDL 3280A/MTIG 7192A; RG 7446/RG 6058; RG7446 42/RG6058 11; RO 5541267/RO 7092284

Latest Information Update: 03 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Roche
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T lymphocyte stimulants; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte inhibitors; TIGIT protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

22 Dec 2022 Preclinical trials in Solid tumours in Switzerland (IV) (NCT05661578)
22 Dec 2022 Roche plans phase II SKYSCRAPER-11 trial (Late-stage disease, Recurrent and Metastatic disease) in Solid tumours (IV) (NCT05661578) (EudraCT Number-2022-001157-23)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com